Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T63068 | Target Info | |||
| Target Name | Serum albumin (ALB) | ||||
| Synonyms |
Serum albumin
Click to Show/Hide
|
||||
| Target Type | Successful Target | ||||
| Gene Name | ALB | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Insulin-degrading enzyme (IDE) | Successful Target | ||||
| UniProt ID | IDE_HUMAN | |||||
| Gene Name | IDE | |||||
| Synonyms |
Insulysin; Insulinase; Insulin protease; Abeta-degrading protease
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 14 nM | [1] | ||
| Co-Target Name | Indoleamine 2,3-dioxygenase 1 (IDO1) | Successful Target | ||||
| UniProt ID | I23O1_HUMAN | |||||
| Gene Name | IDO1 | |||||
| Synonyms |
Indoleamine-pyrrole 2,3-dioxygenase; INDO; IDO-1; IDO
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | Ki = 94 nM | [2] | ||
| Co-Target Name | Soluble epoxide hydrolase (EPHX2) | Clinical trial Target | ||||
| UniProt ID | HYES_HUMAN | |||||
| Gene Name | EPHX2 | |||||
| Synonyms |
Bifunctional epoxide hydrolase 2
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 110 nM | [3] | ||
| Co-Target Name | Macrophage migration inhibitory factor (MIF) | Clinical trial Target | ||||
| UniProt ID | MIF_HUMAN | |||||
| Gene Name | MIF | |||||
| Synonyms |
Phenylpyruvate tautomerase; MMIF; L-dopachrome tautomerase; L-dopachrome isomerase; Glycosylation-inhibiting factor; GLIF; GIF
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | Ki = 570 nM | [4] | ||
| Co-Target Name | Extracellular lysophospholipase D (E-NPP2) | Clinical trial Target | ||||
| UniProt ID | ENPP2_HUMAN | |||||
| Gene Name | ENPP2 | |||||
| Synonyms |
LysoPLD; Ectonucleotide pyrophosphatase/phosphodiesterase family member 2; E-NPP 2; Autotaxin; ATX
Click to Show/Hide
|
|||||
| Representative Drug(s) | EVANS BLUE | Drug Info | Ki = 824 nM | [5] | ||
| Co-Target Name | UDP-glucose 4-epimerase (GALE) | Literature-reported Target | ||||
| UniProt ID | GALE_HUMAN | |||||
| Gene Name | GALE | |||||
| Synonyms |
UDP-galactose4-epimerase; UDP-galactose4'-epimerase; UDP-galactose 4-epimerase; UDP-N-acetylglucosamine 4-epimerase; UDP-N-acetylgalactosamine 4-epimerase; UDP-GlcNAc 4-epimerase; UDP-GalNAc 4-epimerase; Galactowaldenase
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 14 nM | [6] | ||
| Co-Target Name | Histone-lysine N-methyltransferase EHMT2 (EHMT2) | Literature-reported Target | ||||
| UniProt ID | EHMT2_HUMAN | |||||
| Gene Name | EHMT2 | |||||
| Synonyms |
Protein G9a; NG36; Lysine N-methyltransferase 1C; KMT1C; Histone H3-K9 methyltransferase 3; HLA-B-associated transcript 8; H3-K9-HMTase 3; G9A; Euchromatic histone-lysine N-methyltransferase 2; C6orf30; BAT8
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 400 nM | [7] | ||
| Co-Target Name | Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) | Literature-reported Target | ||||
| UniProt ID | EHMT1_HUMAN | |||||
| Gene Name | EHMT1 | |||||
| Synonyms |
EHMT1
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 730 nM | [7] | ||
| Co-Target Name | Heat shock protein 60-Heat shock protein 10 (HSPD1-HSPE1) | Co-Target | ||||
| UniProt ID | CH60_HUMAN-CH10_HUMAN | |||||
| Gene Name | HSPD1-HSPE1 | |||||
| Representative Drug(s) | EVANS BLUE | Drug Info | IC50 = 170 nM | [8] | ||
| Co-Target Name | Gamma-butyrobetaine dioxygenase (BBOX1) | Co-Target | ||||
| UniProt ID | BODG_HUMAN | |||||
| Gene Name | BBOX1 | |||||
| Synonyms |
Gamma-butyrobetaine hydroxylase; Gamma-BBH; Gamma-butyrobetaine,2-oxoglutarate dioxygenase
Click to Show/Hide
|
|||||
| Representative Drug(s) | SPI-1005 | Drug Info | IC50 = 690 nM | [9] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur J Med Chem. 2019 Oct 1;179:557-566. | ||||
| REF 2 | Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Med. Chem. Commun. 2019;10:1740-1754. | ||||
| REF 3 | Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. J Med Chem. 2019 Sep 26;62(18):8443-8460. | ||||
| REF 4 | Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor. J Med Chem. 2018 Sep 27;61(18):8104-8119. | ||||
| REF 5 | Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem. 2010 Apr 22;53(8):3095-105. | ||||
| REF 6 | Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7. | ||||
| REF 7 | Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). Bioorg Med Chem Lett. 2018 Apr 15;28(7):1234-1238. | ||||
| REF 8 | HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules. Bioorg Med Chem Lett. 2019 May 1;29(9):1106-1112. | ||||
| REF 9 | Ejection of structural zinc leads to inhibition of gamma-butyrobetaine hydroxylase. Bioorg Med Chem Lett. 2014 Nov 1;24(21):4954-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.